

### **REMARKS**

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

Applicants thank Examiner Turner for the telephone interview held September 8, 2004 regarding the remaining rejection as discussed below.

#### **I. CLAIM STATUS AND AMENDMENTS**

Claims 13, 16 and 30-38 were pending in this application when last examined.

Claims 13, 16, 30, 31, and 33 are rejected.

Claim 32 is objected to.

Claims 34-38 are withdrawn from consideration as non-elected subject matter.

Claim 13 has been amended to clarify the characteristics of the functional variance of the peptide. Support for this amendment can be found in original claims 1 and 2.

Therefore, no new matter has been added by the amendment.

#### **II. REJECTION UNDER 35 U.S.C. § 102**

Claims 13, 16, 30, 31 and 33 are rejected under 35 U.S.C. § 102(e) as anticipated by Soreq et al., U.S. patent No. 5,932,780. See item 11 on pages 4-5.

This rejection is respectfully traversed for the following reasons.

During the telephonic discussion with the Examiner, it was noted that the current rejection based on the Soreq patent was all ready addressed and overcome by the arguments and the technical information provided in the Declaration of Martin Westwell submitted with the Preliminary Amendment dated October 8, 2002. This rejection is respectfully traversed for the same reasons set forth on pages 11-12 of this prior response. Enclosed is a copy of the Declaration submitted with the prior response.

Again, the only peptides disclosed in the Soreq patent are long C-terminal peptide fragments of acetylcholinesterase (AchE) which are 40-45 amino acid residues long. Such peptides as disclosed in Soreq are incapable of exhibiting calcium channel modulatory function in the same way as the claimed peptide. In this regard, the prior art peptides must be processed to reveal the claimed peptide of SEQ ID NO: 1 and to exhibit the claimed calcium channel modulatory function.

In the instant Office Action, the Examiner referred to column 8, lines 9-20 of the Soreq patent as disclosing a 40-amino acid C-terminal peptide that is a biologically active analogue. However, such peptide is neither functionally nor structurally homologous to the claimed peptide. In fact, the claimed peptide has a new, different and wholly distinct activity and structure from the prior art T40 peptide. See items 3-5 of the Westwell Declaration. In fact, it was determined that the T40 peptide of Soreq and the claimed peptide have very different structures and functions. The Soreq patent is silent with respect to the calcium channel modulatory function of the claimed invention since no such function is present in the C-terminal T40 peptides of Soreq. It is again noted that any activity that the Soreq T40 peptide may have is not enzymatic. Nor does it correspond with the calcium channel modulatory function of the claimed peptide.

Kindly review the Westwell Declaration and again note that the whole T40 peptide must be processed to produce the biological activity exhibited by the claimed peptide.

Therefore, as discussed and agreed to in the telephonic discussion, the Soreq patent fails to disclose or suggest a peptide as encompassed by the claims. Accordingly, the rejection of claims 13, 16, 30, 31 and 33 under 35 U.S.C. § 102(e) is untenable and should be withdrawn.

### **III. CLAIM OBJECTIONS**

Claim 32 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form. See item 13 on page 5.

In view of the above arguments overcoming the anticipation rejection, this objection is no longer tenable and should be withdrawn.

#### **IV. WITHDRAWN CLAIMS**

It is respectfully requested that withdrawn method claims 34-38 be rejoined with the elected product claims.

#### **CONCLUSION**

In view of the foregoing amendments and remarks, it is respectfully submitted that the present application is now in condition for allowance and early notice to that effect is hereby requested.

If Examiner Turner has any comments or proposals for expediting prosecution, please contact the undersigned attorney at the telephone number below.

Respectfully submitted,

Susan A. GREENFIELD et al.

By:



Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/JFW/ksh  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 14, 2004

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

Atty. Docket No. 98-0967A  
Serial No. 09/155,076  
September 14, 2004

**ATTACHMENT TO THE AMENDMENT AND REPLY**

1. Declaration of Martin Westwell (4 pp.)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COPY



In re Application of  
GREENFIELD et al.  
Serial No. 09/155076  
Filed: March 21, 1997  
For: "PEPTIDE FROM SOLUBLE FORM  
OF ACETYLCHOLINESTERASE,  
ACTIVE AS A CALCIUM  
CHANNEL MODULATOR"

DECLARATION

The Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Sir:


I, Martin Westwell, do hereby declare and state as follows:

1. I am a British citizen of 13 Mill Road, Abingdon, Oxfordshire OX14 5NS. I currently hold the position of Research Manager at Synaptica Limited and until 30 June 2001 I was the Research Coordinator of Synaptica Limited and held a fellowship at Lincoln College, Oxford University in biological/medicinal sciences. Synaptica Limited is the assignee of US Patent Application serial no. 09/155076.

2. I have read the comments of the Examiner in the Office Communication dated 22nd June 2001 concerning the above-identified US Patent Application. As a result of my position in Synaptica Limited, I have first hand-knowledge of technical data relevant to the suggestions by the Examiner that whole human acetylcholinesterase (AChE) and the 40 amino acid residue C-terminal fragment of human AChE (the product of exon 6 of the AChE gene) share the calcium channel modulatory function of Synaptica

peptide (the 14mer of SEQ. ID no. 1 as noted in US Patent Application Serial no. 09/155076). These suggestions of the Examiner are wrong as evident from technical data discussed below.

3. Synaptica peptide is contained within the C-terminal 40 mer tail sequence of human AChE (commonly referred to as the T40 peptide) but has both distinct structural and functional characteristics from that longer peptide. In particular, at nanomolar concentrations, Synaptica peptide has been shown to allosterically potentiate the response of the alpha 7 nicotinic receptor to acetylcholine and other agonists of that receptor. The T 40 peptide does not exhibit this modulatory function as shown by the data in Figure 1 below. The data in Figure 1 was obtained using the biotinylated and amidated version of Synaptica peptide. However, additional experiments documented in Published International Application WO 01/73446 of Synaptica Limited (a copy of which is annexed hereto as Exhibit 1) provide further evidence that Synaptica peptide is capable of modulating calcium flux through alpha 7 nicotinic receptors. It will be noted that I am a named inventor on that patent application.



**Figure 1** The positive allosteric effect of the biotinylated and amidated 14-mer can be seen at nanomolar concentrations. The experiments were carried out using Xenopus oocytes injected with  $\alpha 7$  nAChR RNA. Impaled oocytes were superfused with an EC50 concentration of acetylcholine (100  $\mu$ M) and then 100  $\mu$ M acetylcholine plus increasing concentrations of the peptides under study. Data represents the mean  $\pm$  SEM of 4 independent experiments (4 different batches of oocytes)

In keeping with the above-noted different functional activity of T40 peptide and Synaptica peptide, circular dichroism spectroscopy shows that an  $\alpha$ -helical structure


dominates the T40 peptide whereas Synaptica peptide is random coil,  $\beta$ -turns or  $\beta$ -sheet depending upon the conditions.

4. The Examiner is correct that Example 3 of US Patent Application Serial no. 09/155076 suggests that whole AChE causes calcium influx into neurons. However, further experiments such as those described above in Figure 1 indicate that this does not reflect that AChE shares the same non-enzymic mechanism of action as Synaptica peptide. The AChE protein is not a functional analogue of Synaptica peptide. This conclusion is consistent with experiments looking at the ability of G<sub>1</sub> AChE (the recombinant monomeric form of terameric AChE minus the T40 tail) and Synaptica peptide to influence neurite outgrowth of cultured neuronal cells. On cultured hippocampal cells, Synaptica peptide at 1 to 10 nM causes a brief period of neurite outgrowth prior to apoptosis (cell death). Increasing the concentration and/or incubation time of the 14 mer causes a clear apoptotic-necrotic continuum (see Table 1 below). This can be explained in terms of change of calcium flux into the neurons. In contrast, full length G<sub>1</sub> AChE (3 U/ml) causes a robust neurotrophic response (see Figure 2 below) consistent with a different non-cholinergic action from Synaptica peptide. In the same system, T40 peptide has no response on cell survival and/or health.

Incubation time (hours)	[Synaptica peptide]	Mode of cell death
1	1 – 10 nM	Compensatory
24	1 nM – 1 mM	No effect
48	100 nM – 1 $\mu$ M	Apoptosis
72	10 nM – 1 $\mu$ M	Apoptosis
72	10 $\mu$ M – 1 mM	Necrosis
336	10 $\mu$ M – 1 mM	Necrosis
336	1 nM – 1 $\mu$ M	Apoptosis


**Table 1** The action of the 14-mer peptide on cultured hippocampal neurons is dependent on dose and incubation time.


Figure 2: the non-cholinergic ability of AChE to enhance neurite outgrowth of cultured neurons. Organotypic neurons of the substantia nigra were used to show the neurotrophic effect of monomeric AChE. This effect is significant at 100ng/ml.



5. The conclusion must be that processing of whole AChE or the T40 peptide is required to produce the biological activity exhibited by Synaptica peptide. In support of such processing underlying linkage of AChE to neurodegenerative disease causation, it has been shown that Synaptica peptide can be injected into the brains of rats to cause attentional deficit reminiscent of Alzheimer's disease. Such studies are documented in Published International Application no. WO 01/49107, also in the name of Synaptica Limited, a copy of which is annexed as Exhibit 2.

6. All statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true; and further these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such wilful false statements may jeopardize the validity of this declaration, the patent application, or any patents issuing thereon.

  
Martin Westwell

  
Date